SCHEMBL22200827

SCHEMBL22200827

CC(C)n1c(=O)c(-c2ccc(NSCC3CC(F)(F)C3)c(F)c2)nc2cnc(N)nc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.42
MTOR P42345 5/20 0.36
TLR9 Q9NR96 7/20 0.35
TLR8 Q9NR97 7/20 0.35
TLR7 Q9NYK1 7/20 0.35
CYP1A2 P05177 4/20 0.34
CYP3A4 P08684 3/20 0.34
HSD17B10 Q99714 3/20 0.34
USP2 O75604 2/20 0.34
ALDH1A1 P00352 2/20 0.34
PIK3CA P42336 2/20 0.32
TSHR P16473 2/20 0.32
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
GLA P06280 1/20 0.31
ALOX15 P16050 1/20 0.31
CASP1 P29466 1/20 0.31
CASP7 P55210 1/20 0.31
KMT2A Q03164 1/20 0.31
HIF1A Q16665 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200654 0.91 ERN1 (0.42) ERN1MTORTLR9TLR8TLR7
SCHEMBL22200470 0.91 ERN1 (0.42) ERN1MTORTLR9TLR8TLR7
SCHEMBL22200772 0.91 ERN1 (0.41) ERN1MTORTLR9TLR8TLR7
SCHEMBL22200643 0.91 ERN1 (0.42) ERN1MTORTLR9TLR8TLR7
SCHEMBL22200786 0.90 ERN1 (0.43) ERN1MTORTLR9TLR8TLR7
SCHEMBL22200661 0.89 ERN1 (0.41) ERN1MTORTLR9TLR8TLR7
SCHEMBL22200796 0.87 ERN1 (0.40) ERN1MTORTLR9TLR8TLR7
SCHEMBL22200370 0.86 ERN1 (0.42) ERN1MTORTLR9TLR8TLR7
SCHEMBL22200356 0.85 ERN1 (0.41) ERN1MTORCYP1A2CYP3A4HSD17B10
SCHEMBL25034134 0.85 ERN1 (0.50) ERN1MTORTLR9TLR8TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed